Related Experiment Video
Updated: Feb 17, 2026
Intraductal Delivery to the Rabbit Mammary Gland
Published on: March 9, 2017
Neoadjuvant systemic therapy in invasive lobular breast cancer: Is it indicated?
Karen Tsung1, Stephen R Grobmyer2, Chao Tu2
1Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Background:
This study investigated patients with invasive lobular breast carcinoma (ILC) to determine the benefit of neoadjuvant systemic therapy (NAST).
Methods:
Patients with ILC treated from 2006 to 2015 were identified. Tumor characteristics and treatment data were analyzed.
Results:
Of the 560 patients with ILC, 77 patients received NAST. Patients who received NAST presented with larger clinical T stages compared to patients who received surgery first (p < 0.001). Pathological complete response (pCR) to NAST was seen in 17% of patients. Only 14% of patients with clinically positive lymph nodes downstaged to N0. These patients were more likely to have HER2 positive tumors (p < 0.029) and larger tumor size at diagnosis (p < 0.015). Mastectomy was performed in 84% of patients and lumpectomy in 16%.
Conclusions:
Only a minority of patients with ILC achieve pCR. The majority of patients still undergo mastectomy; therefore the benefit of NAST in ILC appears limited.
More Related Videos
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025